Hyalex Orthopaedics is developing HYALEX® Cartilage, a biomimetic polymer designed to replicate the structure and function of native cartilage for use in joint surgeries. This technology addresses the issue of cartilage damage in patients who currently have limited treatment options, aiming to restore joint surfaces effectively during surgical procedures.
Funding
$47.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CPFounders
Product
Problem
Millions of patients suffer from cartilage damage, yet current therapies often fail to adequately restore joint surfaces, leaving a significant unmet need in joint surgery. Existing treatment options provide limited long-term relief and may not fully replicate the natural biomechanical properties of native cartilage.
Solution
Hyalex Orthopaedics is developing HYALEX® Cartilage, a biomimetic polymer designed to replicate the structure and function of native cartilage. The HYALEX® Knee System aims to restore damaged joint surfaces effectively during surgical procedures, offering a potential solution for patients with cartilage damage. This synthetic cartilage platform seeks to provide a more durable and functional alternative to existing cartilage repair techniques. The company's technology has received FDA Breakthrough Device Designation.
Target Audience
The primary target audience includes orthopedic surgeons and patients suffering from cartilage damage who are seeking improved solutions for joint restoration during surgical procedures.
Features
- Biomimetic design replicating the structure and function of native cartilage
- Designed for use in joint surgeries to restore damaged joint surfaces
- Aims to provide a more durable and functional alternative to existing cartilage repair techniques
- HYALEX® Knee System for targeted cartilage restoration in the knee